PMDA approves ENHERTU for HER2-low breast cancer in Japan
200% citation coverage2 regulatory sources
PMDA approved ENHERTU for unresectable or metastatic HER2-low breast cancer in Japan, marking a new regulatory catalyst for Daiichi Sankyo and AstraZeneca. The decision expands the drug’s labeled use in a major market and adds another milestone for investors tracking ENHERTU.
Intelligence Snapshot
Executive Summary
PMDA approved ENHERTU for adult patients with unresectable or metastatic HER2-low breast cancer in Japan.
Key Insights
-
ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate manufactured by…
ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate manufactured by Daiichi Sankyo Inc.
-
In the United States, ENHERTU is FDA-indicated for HER2-positive early breast cancer as…
In the United States, ENHERTU is FDA-indicated for HER2-positive early breast cancer as neoadjuvant and adjuvant treatment, representing a different patient population and HER2 expression profile than the Japan indication.
-
Clinical trials are investigating trastuzumab deruxtecan in HER2-low and HER2-positive…
Clinical trials are investigating trastuzumab deruxtecan in HER2-low and HER2-positive breast cancer settings.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
The Pharmaceuticals and Medical Devices Agency (PMDA) has approved ENHERTU for adult patients with unresectable or metastatic HER2-low breast cancer in Japan. ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate manufactured by Daiichi Sankyo Inc.
Loading intelligence…
Loading intelligence…
Quick Answer
Key Questions
- What did PMDA approve for ENHERTU in Japan?
- Who manufactures ENHERTU?
- What is ENHERTU's mechanism of action?
- What are ENHERTU's FDA-approved indications in the United States?
- What clinical trials are investigating trastuzumab deruxtecan?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track upcoming PDUFA dates and regulatory milestones for drugs in this story.
Unlock full calendar →AstraZeneca AB pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Contents13 sections
PMDA approves ENHERTU for HER2-low breast cancer in Japan
PMDA approval: what changed in Japan
The Pharmaceuticals and Medical Devices Agency (PMDA) has approved ENHERTU for adult patients with unresectable or metastatic HER2-low breast cancer in Japan. ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate, administered intravenously. The generic name is fam-trastuzumab deruxtecan-nxki, manufactured by Daiichi Sankyo Inc.
IntelligenceRegulatory Impact
FDA and EMA decisions frame this story. Regulatory relevance is high for this topic. Track designations, submission types, and label or guidance shifts that could move timelines.
ENHERTU's regulatory footprint extends beyond Japan
In the United States, ENHERTU is FDA-indicated for HER2-positive early breast cancer as neoadjuvant treatment and as adjuvant treatment of adult patients with HER2-positive breast cancer. The Japan approval introduces a distinct indication—HER2-low metastatic disease—that differs from the U.S. label, which focuses on HER2-positive early breast cancer.
IntelligenceMarket Signals
Commercial pull is high and investment relevance high for this topic. Expect implications for pricing, access, and launch sequencing.
Clinical trials involving trastuzumab deruxtecan
A Phase 3 trial (NCT05113251) is evaluating trastuzumab deruxtecan alone or in sequence with taxane, trastuzumab, and pertuzumab versus standard treatment in HER2-positive early breast cancer.
IntelligenceStrategic Takeaways
PMDA approved ENHERTU for adult patients with unresectable or metastatic HER2-low breast cancer in Japan. ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate manufactured by Daiichi Sankyo Inc. In the United States, ENHERTU is FDA-indicated for HER2-positive early breast cancer as neoadjuvant and adjuvant treatment, representing a different patient population and HER2 expression profile than the
Key Takeaways
- PMDA approved ENHERTU for adult patients with unresectable or metastatic HER2-low breast cancer in Japan.
- ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate manufactured by Daiichi Sankyo Inc.
- In the United States, ENHERTU is FDA-indicated for HER2-positive early breast cancer as neoadjuvant and adjuvant treatment, representing a different patient population and HER2 expression profile than the Japan indication.
- Clinical trials are investigating trastuzumab deruxtecan in HER2-low and HER2-positive breast cancer settings.
IntelligenceEvidence Quality
Grounded in 2 regulatory sources.
Drug Snapshot
| Drug | fam-trastuzumab deruxtecan-nxki |
|---|---|
| Generic name | FAM-TRASTUZUMAB DERUXTECAN-NXKI |
| Manufacturer | Daiichi Sankyo Inc. |
| Route | INTRAVENOUS |
| Indication | 1 INDICATIONS AND USAGE ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for: HER2-Positive Early Breast Cancer as neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test followed by a taxane, trastuzumab, and pertuzumab (THP). ( 1.1 ) as adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based treatment. ( 1.1 ) HER2-Positive |
Regulatory Summary
- Approved indication: 1 INDICATIONS AND USAGE ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for: HER2-Positive Early Breast Cancer as neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test followed by a taxane, trastuzumab, and pertuzumab (THP). ( 1.1 ) as adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based treatment. ( 1.1 ) HER2-Positive
- Daiichi Sankyo Inc. develops fam-trastuzumab deruxtecan-nxki
Trial Snapshot
| Trial | Title | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT07198724 | ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer | RECRUITING | PHASE1, PHASE2 | Kristina A. Fanucci |
| NCT05704829 | NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer | RECRUITING | PHASE2 | West German Study Group |
| NCT05113251 | Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 | AstraZeneca |
| NCT07060807 | A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | RECRUITING | PHASE3 | Merck Sharp & Dohme LLC |
| NCT07007559 | ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer | RECRUITING | PHASE2 | ALX Oncology Inc. |
Competitor Matrix
| Company / Program | Indication | Active trials |
|---|---|---|
| Hoffmann-La Roche | breast cancer | 2 |
| Virginia Commonwealth University | breast cancer | 1 |
| Genentech, Inc. | breast cancer | 1 |
| Pfizer | breast cancer | 1 |
| Instituts Supérieurs des Professions Infirmières et Techniques de Santé, Morocco | breast cancer | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | breast cancer | 1 |
Timeline
- Recruiting trial NCT07198724 (PHASE1, PHASE2)
- Recruiting trial NCT05704829 (PHASE2)
- Active_Not_Recruiting trial NCT05113251 (PHASE3)
- Recruiting trial NCT07060807 (PHASE3)
- Recruiting trial NCT07007559 (PHASE2)
Frequently Asked Questions
What did PMDA approve for ENHERTU in Japan?
PMDA approved ENHERTU for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer in Japan.
Who manufactures ENHERTU?
ENHERTU (fam-trastuzumab deruxtecan-nxki) is manufactured by Daiichi Sankyo Inc.
What is ENHERTU's mechanism of action?
ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate administered intravenously.
What are ENHERTU's FDA-approved indications in the United States?
In the United States, ENHERTU is FDA-indicated for HER2-positive early breast cancer as neoadjuvant treatment and as adjuvant treatment of adult patients with HER2-positive breast cancer.
What clinical trials are investigating trastuzumab deruxtecan?
A Phase Ib/II trial (NCT07198724) is exploring trastuzumab deruxtecan combined with elacestrant in HR+/HER2-low or HER2-ultralow metastatic breast cancer. A Phase 3 trial (NCT05113251) is evaluating trastuzumab deruxtecan in HER2-positive early breast cancer.
How does the Japan indication differ from the U.S. label?
The Japan approval covers HER2-low metastatic breast cancer, whereas the FDA-approved indications in the United States focus on HER2-positive early breast cancer, representing different patient populations defined by HER2 expression levels.
Related profiles
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About This Topic
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Stay Updated on Pharma News
Get the latest drug approvals, clinical trials, and regulatory updates delivered to your inbox.
- Sources analyzed
- 1
- Evidence strength
- 100/100
- Last verified
- Jun 10, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Critical source quality · grounded in cited primary and secondary sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
